GSN and head and neck cancer: In agreement with our data, a recent article by Chiu et al. (2020) revealed that a reduced circulating level of plasma gelsolin could be an independent diagnostic biomarker with sensitivity (82.7%) and specificity (95.6%) in head and neck cancer.